Morgan Joseph Reiterates a 'Buy' on Nektar Technology (NKTR); Sees Substantial Added Value From AstraZeneca Deal
More News related to AZN
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
- US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
- Morning Movers 12/03: ICOC, KTCC, FFHL, GNBT, ABK, ISR Higher; PEIX, GRH, OPXA, TRGT, ALOY Lower
- AstraZeneca (AZN) and Targacept (TRGT) To Collaborate to Develop and Commercialize TC-5214 MDD Drug
- Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013
More News related to NKTR
- Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
- Morgan Joseph Reiterates a 'Buy' on Nektar Therapeutics (NKTR)
- Nektar Therapeutics Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Hapoalim Securities Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Ongoing Programs to Help Drive Share Price
More News related to Analyst Comments
- Wedbush Maintains a 'Neutral' on Take-Two Interactive (TTWO), Lowers PT & Estimates
- Soleil Securities Maintains a 'Buy' on Holly Corp. (HOC); Lowers Estimates on Expected Near-Term Pressure
- Brigantine Advisors Maintains a 'Buy' on Marvell (Nasdaq: MRVL); Raises PT & Estimates After Upside Preannouncement
- Goldman Adds CVLT, JNPR and RAX to Conviction Buy List
- Deutsche Bank Maintains a 'Buy' on Home Inns (HMIN); Remains a 'Favorite Idea'
Morgan Joseph reiterates a 'Buy' on Nektar Technology (Nasdaq: NKTR), raises price target from $9 to $12.
Morgan analyst says, "Yesterday, Nektar announced a $1.5 billion worldwide license agreement with AstraZeneca (NYSE: AZN) to develop and market NKTR-118 and NKTR-119. Although we had anticipated a transaction, the size of the deal and the quality of the partner has meaningfully increased our confidence in the potential of NKTR-118, and Nektar's technology. Our key takeaway from this deal is that despite its low development-risk profile, Nektar's technology could add substantial value to shareholders."
To see more analyst ratings on NKTR Click Here.
Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.
Related Categories
Analyst CommentsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
